Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data
74P – Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer
Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP)
Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C)
P2.01-42 Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy
Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities
Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care
Adherence to the 2013 CAP/IASLC/AMP Molecular Testing Guidelines in Non-Small Cell Lung Cancer (NSCLC) in the Community Setting: Opportunities for Improvement
Utilization and clinical impact of genomic profiling for EGFR and ALK in non-squamous non-small cell lung cancer (NSCLC) in the community setting
